This trial is active, not recruiting.

Condition aortic valve stenosis
Treatments bav, without bav
Sponsor Institut für Pharmakologie und Präventive Medizin
Start date April 2014
End date March 2016
Trial size 200 participants
Trial identifier NCT02127580, EASE-IT


There is limited experience for the balloon expandable THV (transcatheter heart valve) on the need for predilation (ballon aortic valvuloplasty, BAV). Therefore we aim to verify results of a small case series published by Wendler et. al. to examine hard endpoints such as the incidence of cerebrovascular complications, paravalvular leakage and operative outcomes in a multicenter registry.

We aim to compare the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
Patients undergoing TA-TAVI WITH predilation of the AV (Group A)
Patients undergoing TA-TAVI WITHOUT predilation of the AV
without bav

Primary Outcomes

VARC2 criteria
time frame: 3 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with an indication for TAVI as to the Edwards THV IFU - Eligible for TABI with AND without BAV - Signed informed consent Exclusion Criteria: - Logistic EuroSCORE I >50% - Mitral or tricuspid valvular insufficiency (> grade II) - Previous aortic valve replacement - Uncontrolled atrial fibrillation - Left ventricular or atrial thrombus by echocardiography - Recent cerebrovascular event (within the last 3 months) - High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)

Additional Information

Official title Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve (EASE-IT) A Two-armed Registry
Principal investigator Holger Schröfel, MD
Description Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty (BAV) is usually performed under rapid right ventricular pacing (burst >180 bpm) with the induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation is aiming at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects, such as: - Functional cardiac arrest induced by rapid pacing leads to transient coronary, cerebral, and renal ischemia. - In patients with a reduced left ventricular ejection fraction (LVEF), prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS). Both are associated with a high periprocedural mortality. - BAV has been identified as a major source of thrombotic and valvular material and increases the risk for coronary obstruction with subsequent myocardial infarction and stroke. - The local trauma in the left-ventricular outflow tract caused by BAV may potentially contribute to aortic root rupture.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Institut für Pharmakologie und Präventive Medizin.